spot on. the company has potential. and they were on their way, until the collapse in october. now, the realization is quite simple, money is needed to fulfill those potentials.
because of the setback, the revenue stream will not be where it should've been by the end of this year and into 2016. they are announcing a new mystery drug latter this year? great! because the announcement is about as far as they will get without funds. if they choose to continuously dilute, we may still be trading in this range at the completion of all those trials regardless of success. does anyone believe that would be best for shareholder value now?
bergerking is already a millionaire, his goal now is to be viewed as the steve jobs of the oncology field. maybe some day his name will be up in lights!...but at what cost?
